Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP) | Zendy

Danwen Yang | Zendy; Rishil J. Kathawala | Zendy; Eduardo E. Chufán | Zendy; Atish Patel | Zendy; Suresh V. Ambudkar | Zendy; ZheSheng Chen | Zendy; Xiang Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP)

Author(s) -

Danwen Yang,

Rishil J. Kathawala,

Eduardo E. Chufán,

Atish Patel,

Suresh V. Ambudkar,

ZheSheng Chen,

Xiang Chen

Publication year - 2013

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon.13.253

Subject(s) - abcg2 , efflux , multiple drug resistance , pharmacology , p glycoprotein , transporter , paclitaxel , atp binding cassette transporter , drug resistance , mitoxantrone , medicine , chemistry , biochemistry , biology , cancer , chemotherapy , microbiology and biotechnology , gene

This study aimed to investigate the mechanism of reversal of multidrug resistance mediated by ABC transporters with tivozanib (AV-951 and KRN-951). Tivozanib is a potent inhibitor of VEGF-1, -2 and -3 receptors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research